MiMedx Group

MDXG

Market cap $1.02B

From a technical perspective, MiMedx Group, Inc (MDXG) is looking like an interesting pick, as it just reached a key level of support. MDXG's 50-day simple moving average crossed above its 200-day simple moving average, which is known as a "golden cross" in the trading world.

Publication of Interim Results and Presentation at Recent Industry Event Demonstrate Clinical Benefit Associated with Use of EPIEFFECT When Compared to Standard of Care (“SOC”)

MARIETTA, Ga., Nov. 10, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that members of its senior management will participate in the following investor conferences: Craig-Hallum 16 th Annual Alpha Select Conference | New York, NY Tuesday, November 18, 20251:1 sessions Canaccord MedTech, Diagnostics and Digital Health & Services Forum | New York, NY Thursday, November 20, 20251:1 sessions Investors interested in meeting with senior management at these events may contact their respective Craig-Hallum or Canaccord representative.

MiMedx Group is positioned for growth, with strong earnings, record Q3 revenue, and a rising contribution from its Surgical business. MDXG is proactively managing 2026 reimbursement policy risks by shifting product mix, accepting near-term price pressure, and leveraging its MiMedx Connect platform. Valuation analysis suggests MDXG is undervalued by ~20%, with feasible revenue growth and FCF margin assumptions supported by recent financial performance.

MARIETTA, Ga., Nov. 03, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today commented on the Centers for Medicare and Medicaid Services (“CMS”) release of the CY 2026 Physician Fee Schedule (“PFS”) final rule, which was published on Friday.

The mean of analysts' price targets for MiMedx (MDXG) points to a 64.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

MiMedx Group, Inc. ( MDXG ) Q3 2025 Earnings Call October 29, 2025 4:30 PM EDT Company Participants Matthew Notarianni - Head of Investor Relations Joseph Capper - CEO & Director Douglas Rice - Chief Financial Officer Conference Call Participants Frank Takkinen - Lake Street Capital Markets, LLC, Research Division Chase Knickerbocker - Craig-Hallum Capital Group LLC, Research Division Carl Byrnes - Northland Capital Markets, Research Division Ross Osborn - Cantor Fitzgerald & Co., Research Division Anthony Petrone - Mizuho Securities USA LLC, Research Division Presentation Operator Good afternoon, and thank you for standing by. Welcome to the MiMedx Third Quarter 2025 Operating and Financial Results Conference Call.

MiMedx (MDXG) came out with quarterly earnings of $0.15 per share, beating the Zacks Consensus Estimate of $0.07 per share. This compares to earnings of $0.07 per share a year ago.

Second Consecutive Quarter of Highest Quarterly Net Sales in MIMEDX History  Third Quarter Net Sales of $114 million Grew 35% Year-Over-Year Third Quarter GAAP Net Income and Diluted Earnings Per Share were $17 Million and $0.11, Respectively Third Quarter Adjusted EBITDA was $35 Million, or 31% of Net Sales Raises 2025 Net Sales Growth and Adjusted EBITDA Expectations Management to Host Conference Call Today, October 29, 2025 , at 4:30 PM ET MARIETTA, Ga., Oct. 29, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), today announced operating and financial results for the third quarter 2025.

MARIETTA, Ga., Oct. 15, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that it will report its operating and financial results for the third quarter ended September 30, 2025 after the market close on Wednesday, October 29, 2025. The MIMEDX senior management team will host a webcast and conference call to review its results beginning at 4:30 p.m. Eastern Time on the same day.